Table 3.
Results of the Randomized, Double-Blind Crossover Clinical Trial of Simvastatin in Healthy Older Adults
| Baseline | Placebo |
Simvastatin |
||||
|---|---|---|---|---|---|---|
| Post-Treatment | Difference | Post-Treatment | Difference | P Value | ||
| Phagocytosis | ||||||
| Escherichia coli | 936.8 (492.4 to 1,675) | 1,497 (1,171 to 2,059) | 690.0 (−79.0 to 1,207) | 1,548 (1,282 to 2,158) | 580 (−22.0 to 1,347) | 0.404 |
| Staphylococcus aureus | 1,291 (660.1 to 2,494) | 1,570 (1,128 to 2,214) | 1,217 (−588.7 to 2,048.0) | 1,525 (997.8 to 1,959) | 257 (−616.7 to 1,951) | 0.196 |
| NETosis | ||||||
| PMA | 47,566 (27,859 to 65,272) | 44,363 (31,546 to 56,273) | 6,964 (−17,992 to 22,048) | 46,974 (32,631 to 55,913) | 5,985 (−24,415 to 30,189) | 0.729 |
| fMLP | 1,570 (−1,029 to 3,416) | −416 (−1,618 to 700) | 1,099 (−2,818 to 2,719) | 3,196 (−2,749 to 6,856) | 1,355 (−2,133 to 6,518) | 0.216 |
| LPS | 1,202 (−1,067 to 2,299) | 1,451 (34.1 to 3,496) | 4,048 (2,833 to 6,279) | 1,202 (−1,067 to 2,299) | 7,115 (−839.1 to 9,851) | 0.596 |
Definition of abbreviations: fMLP = formyl-methionyl-leucyl-phenylalanine; NETosis = neutrophil extracellular trap release by dying cells; PMA = phorbol-12-myristate-13-acetate.
All data are presented as median change and interquartile range with P values derived from Wilcoxon signed-rank tests. Values show baseline median and interquartile range results and the change from baseline neutrophil function after treatment with simvastatin and placebo (n = 20 in each group). Phagocytosis was assessed using the phagocytic index. NETosis was assessed using arbitrary fluorescence units.